Ascentage Pharma Group International balance sheet

At the end of fiscal 2025, Ascentage Pharma Group International had total liabilities of $376m and shareholders' equity of $189m. It held $171m in cash against $284m of debt: net debt of $113m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Ascentage Pharma Group International: balance sheet, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash and equivalents	195	146	122	171
Receivables	—	21	11	36
Inventory	—	2	1	4
Total current assets	—	189	202	421
Goodwill	—	3	3	4
Total current liabilities	—	132	160	235
Short-term debt	—	90	111	176
Long-term debt	—	166	122	108
Total debt	0	256	233	284
Total liabilities	—	342	321	376
Shareholders' equity	59	9	36	189
Net debt (negative = net cash)	−195	109	110	113
Shares outstanding	—	73m	79m	93m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: AAPG vs ADCT AAPG vs PLX AAPG vs BCYC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ascentage Pharma Group International's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ascentage Pharma Group International.